Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.

Lochmann TL, Floros KV, Naseri M, Powell KM, Cook W, March RJ, Stein GT, Greninger P, Maves YK, Saunders LR, Dylla SJ, Costa C, Boikos SA, Leverson JD, Souers AJ, Krystal GW, Harada H, Benes CH, Faber AC.

Clin Cancer Res. 2018 Jan 15;24(2):360-369. doi: 10.1158/1078-0432.CCR-17-1606. Epub 2017 Nov 8.

2.

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.

Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, Oliver TG, Heymach JV, Glisson BS, Wang J, Byers LA.

Oncotarget. 2017 Sep 1;8(43):73419-73432. doi: 10.18632/oncotarget.20621. eCollection 2017 Sep 26.

3.

Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.

Sharma SK, Pourat J, Abdel-Atti D, Carlin SD, Piersigilli A, Bankovich AJ, Gardner EE, Hamdy O, Isse K, Bheddah S, Sandoval J, Cunanan KM, Johansen EB, Allaj V, Sisodiya V, Liu D, Zeglis BM, Rudin CM, Dylla SJ, Poirier JT, Lewis JS.

Cancer Res. 2017 Jul 15;77(14):3931-3941. doi: 10.1158/0008-5472.CAN-17-0299. Epub 2017 May 9.

4.

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.

Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M, Dushin R, Aujay M, Lee C, Ramoth H, Milton M, Hampl J, Lazetic S, Pulito V, Rosfjord E, Sun Y, King L, Barletta F, Betts A, Guffroy M, Falahatpisheh H, O'Donnell CJ, Stull R, Pysz M, Escarpe P, Liu D, Foord O, Gerber HP, Sapra P, Dylla SJ.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaag2611. doi: 10.1126/scitranslmed.aag2611.

PMID:
28077676
5.

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators.

Lancet Oncol. 2017 Jan;18(1):42-51. doi: 10.1016/S1470-2045(16)30565-4. Epub 2016 Dec 5.

6.

Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.

Jahchan NS, Lim JS, Bola B, Morris K, Seitz G, Tran KQ, Xu L, Trapani F, Morrow CJ, Cristea S, Coles GL, Yang D, Vaka D, Kareta MS, George J, Mazur PK, Nguyen T, Anderson WC, Dylla SJ, Blackhall F, Peifer M, Dive C, Sage J.

Cell Rep. 2016 Jul 19;16(3):644-56. doi: 10.1016/j.celrep.2016.06.021. Epub 2016 Jun 30.

7.

Toppling high-grade pulmonary neuroendocrine tumors with a DLL3-targeted trojan horse.

Dylla SJ.

Mol Cell Oncol. 2016 Mar 16;3(2):e1101515. doi: 10.1080/23723556.2015.1101515. eCollection 2016 Mar.

8.

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ.

Sci Transl Med. 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459.

9.

Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.

Damelin M, Bankovich A, Park A, Aguilar J, Anderson W, Santaguida M, Aujay M, Fong S, Khandke K, Pulito V, Ernstoff E, Escarpe P, Bernstein J, Pysz M, Zhong W, Upeslacis E, Lucas J, Lucas J, Nichols T, Loving K, Foord O, Hampl J, Stull R, Barletta F, Falahatpisheh H, Sapra P, Gerber HP, Dylla SJ.

Clin Cancer Res. 2015 Sep 15;21(18):4165-73. doi: 10.1158/1078-0432.CCR-15-0695. Epub 2015 May 26.

10.

Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates.

Anderson WC, Boyd MB, Aguilar J, Pickell B, Laysang A, Pysz MA, Bheddah S, Ramoth J, Slingerland BC, Dylla SJ, Rubio ER.

PLoS One. 2015 May 8;10(5):e0125255. doi: 10.1371/journal.pone.0125255. eCollection 2015.

11.

Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century.

Williams SA, Anderson WC, Santaguida MT, Dylla SJ.

Lab Invest. 2013 Sep;93(9):970-82. doi: 10.1038/labinvest.2013.92. Epub 2013 Aug 5. Review.

12.

Multimodal evaluation of in vivo magnetic resonance imaging of myocardial restoration by mouse embryonic stem cells.

Hendry SL 2nd, van der Bogt KE, Sheikh AY, Arai T, Dylla SJ, Drukker M, McConnell MV, Kutschka I, Hoyt G, Cao F, Weissman IL, Connolly AJ, Pelletier MP, Wu JC, Robbins RC, Yang PC.

J Thorac Cardiovasc Surg. 2008 Oct;136(4):1028-1037.e1. doi: 10.1016/j.jtcvs.2007.12.053. Epub 2008 Jun 6.

13.

Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.

Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, Clarke MF, Hoey T, Lewicki J, Gurney AL.

PLoS One. 2008 Jun 18;3(6):e2428. doi: 10.1371/journal.pone.0002428. Erratum in: PLoS ONE. 2008;3(8). doi: 10.1371/annotation/2aa6a20a-e63c-49b6-aeea-aae62435617f.

14.

Phenotypic characterization of human colorectal cancer stem cells.

Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF.

Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63. Epub 2007 Jun 4.

15.

Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells.

Serafini M, Dylla SJ, Oki M, Heremans Y, Tolar J, Jiang Y, Buckley SM, Pelacho B, Burns TC, Frommer S, Rossi DJ, Bryder D, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Nelson-Holte M, Fine GC, Weissman IL, Blazar BR, Verfaillie CM.

J Exp Med. 2007 Jan 22;204(1):129-39. Epub 2007 Jan 16. Erratum in: J Exp Med. 2007 Jul 9;204(7):1729.

16.

In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery.

Cao F, Lin S, Xie X, Ray P, Patel M, Zhang X, Drukker M, Dylla SJ, Connolly AJ, Chen X, Weissman IL, Gambhir SS, Wu JC.

Circulation. 2006 Feb 21;113(7):1005-14. Epub 2006 Feb 13.

17.

Enforced Bcl-2 expression overrides serum and feeder cell requirements for mouse embryonic stem cell self-renewal.

Yamane T, Dylla SJ, Muijtjens M, Weissman IL.

Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3312-7. Epub 2005 Feb 22.

19.

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL.

N Engl J Med. 2004 Aug 12;351(7):657-67.

20.

Integrin engagement-induced inhibition of human myelopoiesis is mediated by proline-rich tyrosine kinase 2 gene products.

Dylla SJ, Deyle DR, Theunissen K, Padurean AM, Verfaillie CM.

Exp Hematol. 2004 Apr;32(4):365-74.

PMID:
15050747
21.

p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells.

Salesse S, Dylla SJ, Verfaillie CM.

Leukemia. 2004 Apr;18(4):727-33.

PMID:
14961028
22.

BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs).

Chiorean EG, Dylla SJ, Olsen K, Lenvik T, Soignier Y, Miller JS.

Blood. 2003 May 1;101(9):3527-33. Epub 2003 Jan 2.

23.

Phosphatase activity in rat adipocytes: effects of insulin and insulin resistance.

Dylla SJ, Williams JP, Williford J, Hardy RW.

J Cell Biochem. 2000 Apr;77(3):445-54.

PMID:
10760952

Supplemental Content

Loading ...
Support Center